PARP1 and small cell lung carcinoma: Because of the promising activity of PARP inhibitors for patients with SCLC [39, 40], we extended our findings from the NCI-60 and our four isogenic SLFN11-del cell lines to a panel of 36 SCLC cell lines (Table S2).